Results 11 to 20 of about 26,612 (257)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid [PDF]

Frontiers in Immunology, 2019
Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease that mainly affects the elderly. Typical clinical features include the widespread blisters, often preceded by and/or associated with itchy urticarial or eczema ...
Kaisa Tasanen, Outi Varpuluoma, Wataru Nishie   +2 more
doaj   +4 more sources

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report [PDF]

American Journal of Ophthalmology Case Reports, 2023
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old male
Akifumi Matsumoto, Hideki Fukuoka, Akiko Yoneda, Norihiko Yokoi, Chie Sotozono   +4 more
doaj   +2 more sources

Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy [PDF]

SAGE Open Medicine
Background: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic
Abhigan Babu Shrestha, Anupam Halder, Kripa Rajak, Saroj Kumar Jha, Ramesh Lamichhane, Arefin Naher Oishee, Nayanika Tummala Chowdary, Pashupati Pokharel, Sajina Shrestha, Lukash Adhikari, Bikash Adhikari, Aman Rajak, Jalal Haider Khan, Nischal Mainali   +13 more
doaj   +2 more sources

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan [PDF]

Journal of Diabetes Investigation, 2023
Aims/Introduction This study was designed and carried out to investigate the association of dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use with pancreatic cancer (PC) in individuals with diabetes in Japan.
Sodai Kubota, Takuya Haraguchi, Hitoshi Kuwata, Yusuke Seino, Kenta Murotani, Takumi Tajima, Gen Terashima, Makiko Kaneko, Yoshihiro Takahashi, Ken Takao, Takehiro Kato, Kenichiro Shide, Saeko Imai, Atsushi Suzuki, Yasuo Terauchi, Yuichiro Yamada, Yutaka Seino, Daisuke Yabe   +17 more
doaj   +2 more sources

The role of dipeptidyl peptidase-4 inhibitors

BMJ, 2012
Will be clearer once ongoing trials are complete Type 2 diabetes is a progressive disease and greater treatment intensity is needed over time to control increasingly abnormal glucose concentrations.1 In the linked article (doi:10.1136/bmj.e1369), Karagiannis and colleagues present a systematic review and meta-analysis of the risks and benefits ...
Lasserson, D, Mant, J
openaire   +4 more sources

Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non‐randomized controlled trials in Japan: A systematic review

Journal of Diabetes Investigation, 2023
Aims/Introduction This study aimed to understand the characteristics of type 2 diabetes subjects enrolled in randomized controlled trials (RCTs) and non‐RCTs according to therapeutic regimens through systematic literature review.
Takashi Kadowaki, Ayako Shoji, Yurie Taguchi   +2 more
doaj   +1 more source

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors [PDF]

BioMed Research International, 2014
A cell surface serine protease, dipeptidyl peptidase 4 (DPP-4), cleaves dipeptide from peptides containing proline or alanine in the N-terminal penultimate position. Two important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), enhance meal-stimulated insulin secretion from pancreaticβ-cells, but ...
Kim, Na-Hyung, Yu, Taeyang, Lee, Dae Ho
openaire   +2 more sources

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Clinical Case Reports, 2020
We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara, Toshie Iijima, Shintaro Sakurai, Teruo Jojima, Eriko Ohira, Shujiro Hayashi, Isao Usui, Ken Igawa, Yoshimasa Aso   +8 more
doaj   +1 more source

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

Frontiers in Immunology, 2022
Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto   +8 more
doaj   +1 more source

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats

Journal of Pharmacological Sciences, 2004
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-
Kotaro Takasaki, Takao Nakajima, Kimihisa Ueno, Yuji Nomoto, Katsuya Higo   +4 more
doaj   +1 more source